Alternatively, compounds, such as ligand analogs or antibodies, that bind to MTR-3, but do not activate the protein can be effective in inhibiting MTR-3 proteinactivity.Further, antisense and ribozyme molecules which inhibit expression of the MTR-3 genes of the present invention may also be used in accordance with the invention to inhibit aberrant MTR-3 gene activity.